Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

Overview

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how anastrozole effects postmenopausal women who have undergone surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.

Full Title of Study: “Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2007

Detailed Description

OBJECTIVES: Primary – Determine the 12-month change in breast density in postmenopausal women with ductal carcinoma in situ (DCIS) or stage I-III breast cancer treated with adjuvant anastrozole. Secondary – Determine the change in estrone sulfate levels in patients treated with this drug. – Correlate the change in breast density with the change in circulating estrone sulfate levels in patients treated with this drug. – Determine the frequency of polymorphisms in aromatase (CYP19) and evaluate the relationship between wild-type aromatase enzyme with change in breast density and change in estrone sulfate levels in patients treated with this drug. – Determine the 12-month change in bone density, and correlate it with the change in circulating estrone sulfate levels in patients treated with this drug. – Correlate the reversal of hypermethylation with change in circulating estrone sulfate levels and breast density in patients treated with this drug. OUTLINE: This is a pilot study. Patients are stratified according to concurrent bisphosphonate use (yes vs no). Patients receive oral anastrozole once daily for up to 12 months in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Interventions

  • Drug: anastrozole
    • 1 mg orally daily for 12 months
  • Procedure: adjuvant therapy
    • treatment received after breast cancer surgery

Arms, Groups and Cohorts

  • Experimental: Anastrozole
    • Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer

Clinical Trial Outcome Measures

Primary Measures

  • Change in breast density after 12 months of treatment
    • Time Frame: 12 months

Secondary Measures

  • Change in hormone levels after 12 months of treatment
    • Time Frame: 12 months
  • Comparison between change in breast density with change in hormone levels after 12 months of treatment
    • Time Frame: 12 months
  • Comparison between the frequency of aromatase polymorphisms with changes in breast density and hormone levels after 12 months of treatment
    • Time Frame: 12 months
  • Comparison between change in bone density with change in hormone levels after 12 months of treatment
    • Time Frame: 12 months
  • Comparison between tissue methylation with changes in breast density and hormone levels after 12 months of treatment
    • Time Frame: 12 months

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Histologically confirmed breast cancer meeting 1 of the following criteria: – Ductal carcinoma in situ (DCIS) – Invasive carcinoma – Stage I-III disease – Must have undergone breast cancer surgery within the past 6 months, including any of the following: – Mastectomy or lumpectomy with or without radiation – Sentinel node and/or axillary node dissection – Re-excision of lumpectomy margins – Intact contralateral breast – No prior radiation therapy or mastectomy – Prior biopsies allowed – Hormone receptor status: – Estrogen and/or progesterone receptor-positive tumor by immunohistochemical staining PATIENT CHARACTERISTICS: Sex – Female Menopausal status – Postmenopausal, defined as 1 of the following: – At least 60 years of age – Less than 60 years of age and amenorrheic ≥ 12 months prior to study entry – Less than 60 years of age, amenorrheic for < 12 months prior to day 1, and luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within postmenopausal range – Less than 60 years of age, without a uterus, and LH and FSH values within postmenopausal range – Underwent prior bilateral oophorectomy – Underwent prior radiation castration AND amenorrheic for ≥ 6 months Performance status – ECOG 0-2 Life expectancy – Not specified Hematopoietic – Not specified Hepatic – Not specified Renal – Not specified PRIOR CONCURRENT THERAPY: Chemotherapy – No prior or concurrent adjuvant chemotherapy for breast cancer Endocrine therapy – No prior aromatase inhibitor – At least 6 weeks since prior and no concurrent tamoxifen – At least 6 weeks since prior and no concurrent hormone replacement therapy – Concurrent low-dose, local vaginal estrogen in the form of either a conjugated estrogen ring or other similar product (e.g., Estring® or Vagifem®) allowed – At least 6 weeks since prior and no other concurrent selective estrogen receptor modulators (e.g., raloxifene) Radiotherapy – See Disease Characteristics Surgery – See Disease Characteristics – No contralateral breast implant Other – Concurrent bisphosphonates allowed at the discretion of the treating oncologist – No concurrent consumption of soy supplements – Concurrent routine dietary consumption of soy-containing foods allowed – No other concurrent investigational or commercial drugs or therapies for the treatment of DCIS or invasive breast cancer

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Vered Stearns, MD, Study Chair, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Citations Reporting on Results

Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.